Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Bavarian Nordic A/S (BV3A.F)

Compare
6.45
-0.20
(-3.01%)
At close: April 17 at 3:29:02 PM GMT+2
Loading Chart for BV3A.F
  • Previous Close 6.65
  • Open 6.80
  • Bid 6.65 x --
  • Ask 6.80 x --
  • Day's Range 6.45 - 6.80
  • 52 Week Range 5.75 - 14.80
  • Volume 500
  • Avg. Volume 10
  • Market Cap (intraday) 1.58B
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) 11.52
  • EPS (TTM) 0.56
  • Earnings Date May 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

www.bavarian-nordic.com

1,605

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BV3A.F

View More

Performance Overview: BV3A.F

Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

BV3A.F
22.75%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

1-Year Return

BV3A.F
0.78%
OMX Copenhagen 25 Index (^OMXC25)
19.44%

3-Year Return

BV3A.F
34.18%
OMX Copenhagen 25 Index (^OMXC25)
0.00%

5-Year Return

BV3A.F
34.18%
OMX Copenhagen 25 Index (^OMXC25)
25.76%

Compare To: BV3A.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BV3A.F

View More

Valuation Measures

Annual
As of 4/17/2025
  • Market Cap

    1.58B

  • Enterprise Value

    1.31B

  • Trailing P/E

    11.47

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.97

  • Price/Book (mrq)

    0.99

  • Enterprise Value/Revenue

    1.71

  • Enterprise Value/EBITDA

    5.83

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.28%

  • Return on Assets (ttm)

    4.60%

  • Return on Equity (ttm)

    9.09%

  • Revenue (ttm)

    5.72B

  • Net Income Avi to Common (ttm)

    987.98M

  • Diluted EPS (ttm)

    0.56

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.18B

  • Total Debt/Equity (mrq)

    1.39%

  • Levered Free Cash Flow (ttm)

    -421M

Research Analysis: BV3A.F

View More

Company Insights: BV3A.F

Research Reports: BV3A.F

View More